NeurogesX to Hold Conference Call to Discuss Third Quarter 2010 Results

SAN MATEO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will hold a conference call on Wednesday, November 3, 2010 at 8:30 a.m. EDT (5:30 a.m. PDT) to report results for its third quarter ended September 30, 2010.

The conference call will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Executive Vice President, Chief Operating Officer and Chief Financial Officer.

To participate, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International).  To access the live web cast please visit the Investor Relations section on the corporate web site at http://www.neurogesx.com.

A replay of the conference call will be available beginning November 3, 2010 at 11:30 a.m. EDT (8:30 a.m. PDT) and ending on November 13, 2010 by dialing 1-877-870-5176 (USA) or 1-858-384-5517 (International) with Conference ID Number: 359770.  A replay of the webcast will also be available on the corporate website through December 3, 2010.

About NeurogesX, Inc.

NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The Company is currently preparing to submit a supplemental NDA for Qutenza for the management of pain due to  HIV- distal sensory neuropathy , or HIV-DSP, also known as HIV-associated neuropathy, or HIV-AN.  Additionally, the Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 studies.

The Company's early-stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements about the preparation and potential submission of a label expansion NDA for Qutenza. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the submission of the supplemental NDA for Qutenza; data submitted may not be sufficient to support FDA approval of Qutenza in the treatment of pain associated with HIV-AN; market acceptance of Qutenza in already approved indications may not be sufficient to support further pursuit of an expanded label for Qutenza, including as a result of physician or patient reluctance to use Qutenza; Qutenza and NeurogesX' other product candidates may have unexpected adverse side effects; and potential alternative therapies. For further information regarding these and other risks related to NeurogesX's business, investors should consult NeurogesX's filings with the Securities and Exchange Commission.

SOURCE NeurogesX